[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513189":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":41,"centralContacts":45,"locations":55,"responsibleParty":75,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":30,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":30,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":58,"whyStopped":30,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"S-nicotine (tobacco) as the starting condition","EXPERIMENTAL","Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.",[13,14,15],"Drug: (S)-Nicotine","Drug: (R)- nicotine","Drug: Racemic nicotine",{"label":17,"type":10,"description":18,"interventionNames":19},"R-nicotine (synthetic) as the starting condition","Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Racemic (50:50 S- and R- nicotine) as the starting condition","Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.",[13,14,15],[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","(S)-Nicotine","Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.",[17,21,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"(R)- nicotine","Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 100% (R)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.",[17,21,9],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Racemic nicotine","Participants will spend 8 hours in the hospital research ward and will vape e-liquid containing 50% (R)-nicotine and 50% (S)-nicotine. They will vape following a standardized session, followed by a 4 hour abstinence period. Participants will then vape as they wish (ad libitum) for 90 minutes.",[17,21,9],[40],"50:50 mixture of (S)- and (R)-nicotine",[42],{"name":43,"affiliation":5,"role":44},"Neal Benowitz, MD","PRINCIPAL_INVESTIGATOR",[46,51],{"name":47,"role":48,"phone":49,"phoneExt":30,"email":50},"Lisa Lawrence","CONTACT","628-206-4204","lisa.lawrence@ucsf.edu",{"name":52,"role":48,"phone":53,"phoneExt":30,"email":54},"Armando Barraza","510-560-4842","armando.barraza@ucsf.edu",[56],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Zuckerberg San Francisco General Hospital (ZSFG)","RECRUITING","San Francisco","California","94110","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-122.41942,37.77493,{"lat":68,"lon":67},[71,73,74],{"name":47,"role":48,"phone":72,"phoneExt":30,"email":50},"415-502-2465",{"name":52,"role":48,"phone":72,"phoneExt":30,"email":54},{"name":43,"role":44,"phone":30,"phoneExt":30,"email":30},{"type":76,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[78],{"name":79,"class":80},"National Institute on Drug Abuse (NIDA)","NIH","100513189","phase-1-comparative-pharmacokinetics-and-pharmacodynamics-of-synthetic-nicotine-100513189",false,"NCT05962229","Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine","Inclusion Criteria:\n\n* Healthy on the basis of medical history and limited physical examination.\n* Current regular user of E-Cigarettes (≥ 15 days in the past 30 days)\n\nExclusion Criteria:\n\n* • Medications\n\n  * Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).\n  * Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers).\n  * Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum).\n  * Any stimulant medications (example: Adderall) generally given for ADHD treatment.\n\n    • Pregnancy\n  * Pregnancy (self-reported and urine pregnancy test)\n  * Breastfeeding (determined by self-report)\n  * Women of childbearing potential must be using an acceptable method of contraception\n\n    * Inability to read and write in English\n    * A known propylene glycol\u002Fvegetable glycerin allergy\n    * Uncomfortable with getting blood drawn",true,"ALL","21 Years","65 Years",{"count":92,"type":93},18,"ESTIMATED","INTERVENTIONAL",[96],"PHASE1","In a crossover study, experienced electronic cigarette users will vape 3 different forms of nicotine: natural (derived from tobacco), synthetic, or a 50:50 mixture of both natural and synthetic. The investigators will compare nicotine metabolism, cardiovascular effects, patterns of self-administration, and participants' feelings of craving\u002Fwithdrawal and enjoyment.",[99,100],"Nicotine Dependence","Nicotine Vaping",[102,103,104,105],"Nicotine Pharmacokinetics","Nicotine Pharmacodynamics","Vaping","E-cigarettes","2026-05-12",{"date":108,"type":109},"2026-05-14","ACTUAL",{"date":111,"type":109},"2024-12-06",{"date":113,"type":93},"2027-05",{"name":5,"class":6},1]